By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Biocartis said today that it has raised €30 million ($41.3 million) in a Series B financing round.

Swiss biopharmaceutical conglomerate Debiopharm and Johnson & Johnson Development Corporation participated in the financing round as new investors, each thus obtaining a minority stake in Luassane, Switzerland-based Biocartis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.